U.S. Markets closed

How GlaxoSmithKline’s Revenues Are Trending in Fiscal 2019

Margaret Patrick
How GlaxoSmithKline’s Revenues Are Trending in Fiscal 2019

The launch of Mylan’s Wixela Inhub, the generic version of Advair, was a key factor driving down GlaxoSmithKline’s Established Pharmaceuticals revenues.